These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of unenhanced computed tomography and Delivanis DA; Bancos I; Atwell TD; Schmit GD; Eiken PW; Natt N; Erickson D; Maraka S; Young WF; Nathan MA Clin Endocrinol (Oxf); 2018 Jan; 88(1):30-36. PubMed ID: 28815667 [TBL] [Abstract][Full Text] [Related]
4. Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using Jha A; Patel M; Carrasquillo JA; Ling A; Millo C; Saboury B; Chen CC; Wakim P; Gonzales MK; Meuter L; Knue M; Talvacchio S; Herscovitch P; Rivero JD; Chen AP; Nilubol N; Taïeb D; Lin FI; Civelek AC; Pacak K AJR Am J Roentgenol; 2022 Feb; 218(2):342-350. PubMed ID: 34431366 [No Abstract] [Full Text] [Related]
5. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions. Ciftci E; Turgut B; Cakmakcilar A; Erturk SA Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494 [TBL] [Abstract][Full Text] [Related]
6. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results. Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252 [TBL] [Abstract][Full Text] [Related]
7. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167 [TBL] [Abstract][Full Text] [Related]
8. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses. Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Importance of Bone Marrow Uptake on Baseline Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313 [TBL] [Abstract][Full Text] [Related]
10. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687 [TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET versus (18)F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients. Sung YM; Lee KS; Kim BT; Choi JY; Chung MJ; Shim YM; Yi CA; Kim TS Korean J Radiol; 2008; 9(1):19-28. PubMed ID: 18253072 [TBL] [Abstract][Full Text] [Related]
12. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Yi JH; Kim SJ; Choi JY; Ko YH; Kim BT; Kim WS Hematol Oncol; 2010 Jun; 28(2):57-61. PubMed ID: 19593742 [TBL] [Abstract][Full Text] [Related]
13. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions? Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709 [TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT in the evaluation of adrenal masses. Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184 [TBL] [Abstract][Full Text] [Related]
15. Distinct FDG PET/CT avidity among newly diagnosed intravascular large B-cell lymphoma patients: a descriptive observational study. Zhao D; Zhang Y; Zhu W; Huo L; Zhou D; Wang W; Wei C; Zhang W Ann Hematol; 2024 Feb; 103(2):545-552. PubMed ID: 37932469 [TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
17. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. Boland GW; Blake MA; Holalkere NS; Hahn PF AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700 [TBL] [Abstract][Full Text] [Related]
18. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046 [TBL] [Abstract][Full Text] [Related]